Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2–specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 217; no. 11
Main Authors Schmidt, Fabian, Weisblum, Yiska, Muecksch, Frauke, Hoffmann, Hans-Heinrich, Michailidis, Eleftherios, Lorenzi, Julio C.C., Mendoza, Pilar, Rutkowska, Magdalena, Bednarski, Eva, Gaebler, Christian, Agudelo, Marianna, Cho, Alice, Wang, Zijun, Gazumyan, Anna, Cipolla, Melissa, Caskey, Marina, Robbiani, Davide F., Nussenzweig, Michel C., Rice, Charles M., Hatziioannou, Theodora, Bieniasz, Paul D.
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 02.11.2020
Subjects
Animals
Antibodies, Monoclonal - immunology
Antibodies, Neutralizing - analysis
Antibodies, Neutralizing - blood
Antibodies, Viral - analysis
Antibodies, Viral - blood
Betacoronavirus - genetics
Betacoronavirus - immunology
Cell Line
Chimera - genetics
Chimera - immunology
Chlorocebus aethiops
Coronavirus Infections - immunology
Coronavirus Infections - virology
COVID-19
HEK293 Cells
HIV-1 - genetics
HIV-1 - immunology
Humans
Immunoassay - methods
Infectious Disease and Host Defense
Neutralization Tests - methods
Pandemics
Pneumonia, Viral - immunology
Pneumonia, Viral - virology
Recombination, Genetic
SARS-CoV-2
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Technical Advances and Resources
Vero Cells
Vesicular stomatitis Indiana virus - genetics
Vesicular stomatitis Indiana virus - immunology
Online AccessGet full text

Cover

More Information
Summary:The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2–specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Disclosures: F. Schmidt reported a patent to VSV/SARS-CoV-2 chimeric virus pending. Y. Weisblum reported a patent to patent on VSV/SARS-CoV-2 chimeric virus pending. D.F. Robbiani reported a patent to monoclonal antibodies against SARS-CoV-2 pending. M.C. Nussenzweig reported a patent to anti-SARS-2 antibodies pending, "Rockefeller University," and is an inventor on the anti-SARS-2 antibody patent that has been submitted by the Rockefeller University. P.D. Bieniasz reported a patent to VSV/SARS-CoV-2 patent pending. No other disclosures were reported.
F. Schmidt, Y. Weisblum, and F. Muecksch contributed equally to this paper.
ISSN:0022-1007
1540-9538
1540-9538
DOI:10.1084/jem.20201181